KZIA (Kazia Therapeutics) Beginning Cash Position: $2.89 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KZIA Kazia Therapeutics Ltd KZIA
33 GF Score
Price $12.48
! 5 Warning Signs
View Full Analysis

What is Kazia Therapeutics Beginning Cash Position?

Kazia Therapeutics KZIA +3.96% 33 Beginning Cash Position is $2.89 Mil as of Dec. 2025. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review.

Kazia Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2025 was $2.89 Mil.

Kazia Therapeutics's quarterly Beginning Cash Position increased from Dec. 2024 ($1.05 Mil) to Jun. 2025 ($2.00 Mil) and increased from Jun. 2025 ($2.00 Mil) to Dec. 2025 ($2.89 Mil).

Kazia Therapeutics's annual Beginning Cash Position declined from Jun. 2023 ($4.94 Mil) to Jun. 2024 ($3.48 Mil) and declined from Jun. 2024 ($3.48 Mil) to Jun. 2025 ($1.08 Mil).

Kazia Therapeutics Beginning Cash Position Related Terms

Kazia Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Kazia Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kazia Therapeutics Beginning Cash Position Chart

Kazia Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.70 19.39 4.94 3.48 1.08

Kazia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 2.37 1.05 2.00 2.89
KZIA
33GF Score
Kazia Therapeutics Ltd KZIA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kazia Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.89 Mil mean?
Kazia Therapeutics (KZIA) has a Beginning Cash Position of $2.89 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Kazia Therapeutics and its competitors.
Is Kazia Therapeutics' Beginning Cash Position too high?
Kazia Therapeutics' current Beginning Cash Position is $2.89 Mil. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' Beginning Cash Position compare to OKUR and TNYA?
Kazia Therapeutics' Beginning Cash Position of $2.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Kazia Therapeutics and its competitors. Kazia Therapeutics's current Beginning Cash Position is $2.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current Beginning Cash Position of $2.89 Mil. The current Beginning Cash Position is $2.89 Mil. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current Beginning Cash Position is $2.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kazia Therapeutics Business Description

Address 300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score

Get the complete analysis for KZIA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.48
Price